Last mentioned: Mar 13, 2026
Perspective Therapeutics and Assertio Holdings are preparing to release their Q4 2025 financial results, highlighting a critical juncture for both the radiopharmaceutical biotech and specialty pharma sectors. Investors are focused on clinical trial milestones for Perspective and portfolio optimization strategies for Assertio.
Perspective Therapeutics and Assertio Holdings are preparing to report Q4 2025 results, with investors focused on Perspective's radiopharmaceutical pipeline and Assertio's commercial execution of its expanded portfolio. These reports will provide critical updates on clinical milestones and revenue diversification strategies for both specialty players.
Perspective Therapeutics and Assertio Holdings are set to report Q4 2025 results, highlighting a divergence between the high-growth radiopharmaceutical sector and the specialty pharma market. Investors are focused on Perspective's clinical pipeline progress and Assertio's efforts to stabilize its commercial portfolio.